We are very pleased to announce that the national launch of our FDA-approved Next Generation Caldolor product!


Caldolor was originally approved in a vial presentation. The new formulation of Caldolor comes in a ready-to-use, pre-mixed bag containing 800 mg of ibuprofen in a patented formulation. This new presentation will provide healthcare professionals with a formulation that is ready to use and easy to administer. It’s the first and only FDA-approved pre-mixed bag of ready-to-use, injectable ibuprofen.


The misuse of and growing addiction to opioids is a national crisis. As we all know, the opioid crisis in America is a public health emergency. And every day, over 130 Americans die of an opioid overdose, according to The Centers for Disease Control and Prevention.


There is a growing body of literature demonstrating that use of Caldolor in hospitals can significantly decrease both surgical pain and the need for opioids in the patients who receive it. Administering Caldolor just prior to surgery, during surgery and throughout the postoperative period, has resulted in patients experiencing significantly less pain immediately after surgery, remaining in less pain afterwards, and subsequently reducing the patients’ need for opioids.


Clinical studies of Caldolor demonstrate:

Up to a 58% reduction in opioid use compared to placebo group

Up to a 43% reduction in VAS scores at rest compared to opioids alone

Patients reporting significantly less pain shortly after waking

Patients remain in significantly less pain during recovery

Potential to improve quality of recovery and reduce postsurgical fatigue

Significant pain and fever reduction in children ages six months and older


For more information, visit cumberlandpharma.com